As medicine progresses into a new era of personalized therapy, therapeutic antibodies are leading the charge and have grown into a billion-euro industry. Antibodies present an attractive option for a wide variety of common diseases because of their specificity and flexibility. Major blockbusters like Humira, Remicade, MabThera, Avastin, and Herceptin are therapeutic antibodies, which represent today the fastest growing group of biotechnology-derived molecules in clinical trials.